Pittsburgh (ots/PRNewswire) -
- Promoted from Head of North America
Mylan Inc. (NYSE: MYL) today announced the appointment of Heather
Bresch as Chief Operating Officer. Ms. Bresch served previously as
Head of North America and Chief Integration Officer. As Chief
Operation Officer, Ms. Bresch will be responsible for Mylan's global
commercial and technical operations, strategic planning, business
development and international affairs, which includes development of
Mylan's antiretroviral (ARV) franchise. She will also continue to
oversee the integration of Mylan's recent acquisition of Merck
Ms. Bresch has spent fifteen years with Mylan in various positions
of increasing responsibility throughout the company. Most recently,
as Head of North America, she had responsibility for Mylan's
operations including Mylan Pharmaceuticals, Mylan Technologies, and
UDL Laboratories. Prior to this, she served as Senior Vice President
of Strategic Development in the Office of the CEO.
In her role as Chief Integration Officer, in addition to leading
the integration team working with Merck Generics, Ms. Bresch has
overseen the successful integration of Matrix Laboratories, in which
Mylan took a controlling stake earlier this year.
Ms. Bresch has been the only non-CEO to serve as Chairman of the
Generic Pharmaceutical Association (GPhA), serving an unprecedented
two consecutive terms, and is widely acknowledged in the industry for
playing a critical role in the passage of the 2003 Medicare
Modernization Act, a Congressional revision to the Hatch-Waxman Act
of 1984 that focused on ensuring consumers' access to affordable
Mylan's Vice Chairman and CEO Robert J. Coury commented: "At this
stage in Mylan's history, it is imperative that we have a Chief
Operating Officer in place that knows our company, is a leader in the
industry and has the experience and energy required to execute on the
opportunities of the new Mylan. Heather is uniquely qualified for
this challenging position, given her in-depth knowledge of Mylan,
Matrix and Merck Generics and her strong relationships with
management and employees across those organizations as a result of
leading the integration efforts. She has played an instrumental role
in Mylan's strategic development over the last several years, and
will continue to be a key driver of the Company's future success."
Ms. Bresch earned an MBA and an undergraduate degree in
international studies and political science from West Virginia
Mylan Inc. is one of the world's leading quality generic and
specialty pharmaceutical companies. The Company offers one of the
industry's broadest and highest quality product portfolios, a robust
product pipeline and a global commercial footprint through operations
in more than 90 countries. Through its controlling interest in Matrix
Laboratories Limited, Mylan has direct access to one of the largest
active pharmaceutical ingredient (API) manufacturers in the world.
Dey L.P., Mylan's fully integrated specialty business, provides the
Company with innovative and diversified opportunities in the
respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
Web site: http://www.mylan.com
ots Originaltext: Mylan Inc.
Im Internet recherchierbar: http://www.presseportal.ch
Kris King, Mylan Inc., +1-724-514-1800